PPD and Siemens-backed biopharmaeutical developer Liquidia Technologies has filed to raise up to $57.5m in its initial public offering.
US-based biopharmaceutical company Liquidia Technologies has filed for a $57m initial public offering that will enable research services provider PPD and industrial technology producer Siemens to exit.
Liquidia is developing therapeutics based on Print, a particle engineering platform spun off from research conducted by eminent professor of chemistry Joseph DeSimone and Edward Samulski, chairman of the Department of Applied Physical Sciences, at University of North Carolina (UNC).
The IPO proceeds will support an ongoing phase 3 clinical trial for…
